Floatz logo

Cilofexor

Non Alcoholic Fatty Liver Disease

Phenex Pharmaceuticals AGSmall moleculePhase 2Dormant
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
95/ 100

Competitive context

140 Active assets in the Non Alcoholic Fatty Liver Disease cohort.

Asset / SponsorPhaseRating
Dapagliflozin
Post Graduate Institute of Medical Education and Research, Chandigarh
Phase 4BBB
Empagliflozin
Justin Ryder
Phase 4BBB
Exenatide
Fudan University
Phase 4BBB
Metformin
Xiqiao Zhou
Phase 4BBB
Pioglitazone
Badr University
Phase 4BBB

View all 50 →

Same molecule, other indications

Cilofexor is also rated in:

metabolic dysfunction-associated steatohepatitisDormant
B
Indicative ·
63 / 100
View asset →
primary sclerosing cholangitisDormant
B
Indicative ·
59 / 100
View asset →
primary biliary cholangitisDormant
CCC
Indicative ·
51 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →